Related Experiment Video
Updated: Nov 16, 2025
Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses
Published on: December 29, 2015
Monoclonal Antibody That Inhibits Cleavage Activity of Japanese Encephalitis Virus NS3
Yi Kai1,2, Xie Lilan1,2, Li Yaoming1,2
1Hubei Engineering Research Center of Viral Vector, Applied Biotechnology Research Center, Wuhan University of Bioengineering, Wuhan, China.
Abstract:
Flavivirus protease has been deemed a potential target for drug and therapeutics development due to its crucial role in viral replication. In this study we prepared a monoclonal antibody (mAb) against nonstructural protein 3 (NS3) protease portion of Japanese encephalitis virus (JEV), and evaluated its inhibitory effect for NS3 protease activity. First, a JEV NS3 protease-specific mAb (designated 2C2) was generated by the traditional cell fusion technique. Second, the binding specificity of 2C2 for NS3 protease was determined by indirect fluorescent assay and Western blotting. Finally, inhibitory effect of 2C2 for NS3 protease cleaving human stimulator of interferon gene was evaluated. Therefore, mAb 2C2 provides a potential diagnostic tool for differential diagnosis for patients who have been vaccinated with inactivated vaccine or naturally infected, and might be genetically reconstructed and optimized for new therapeutics development.
Insights
Researchers developed a monoclonal antibody (mAb) targeting the Japanese encephalitis virus (JEV) nonstructural protein 3 (NS3) protease. This antibody shows potential for diagnostics and therapeutic development against JEV infections.
Area of Science:
- Virology
- Immunology
- Drug Discovery
Background:
- Flavivirus proteases are critical for viral replication and represent potential therapeutic targets.
- Japanese encephalitis virus (JEV) is a significant flavivirus with implications for public health.
Purpose of the Study:
- To generate and characterize a monoclonal antibody (mAb) against the JEV nonstructural protein 3 (NS3) protease.
- To evaluate the inhibitory potential of the mAb on NS3 protease activity and its utility in diagnostics and therapeutics.
Main Methods:
- Generation of a JEV NS3 protease-specific mAb (2C2) using cell fusion.
- Assessment of mAb 2C2 binding specificity via indirect fluorescent assay and Western blotting.
- Evaluation of mAb 2C2's inhibitory effect on NS3 protease-mediated cleavage of human stimulator of interferon gene.
Main Results:
- A specific mAb, designated 2C2, was successfully generated against the JEV NS3 protease.
- The binding specificity of 2C2 to JEV NS3 protease was confirmed.
- mAb 2C2 demonstrated an inhibitory effect on NS3 protease activity.
Conclusions:
- mAb 2C2 is a valuable tool for the differential diagnosis of JEV infection and vaccination.
- The antibody holds potential for genetic reconstruction and optimization for novel therapeutic strategies against JEV.
